UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Journal of clinical oncology, 2011-10, Vol.29 (29), p.3907-3913

2011

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

International journal of molecular sciences, 2021-03, Vol.22 (7), p.3530

2021

Volltextzugriff (PDF)

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Journal of clinical oncology, 2012-11, Vol.30 (33), p.4098-4103

2012

Volltextzugriff (PDF)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project

Biomedicines, 2023-07, Vol.11 (7), p.1925

2023

Volltextzugriff (PDF)

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis

Journal of clinical oncology, 2017-12, Vol.35 (34), p.3844-3850

2017

Volltextzugriff (PDF)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Experimental hematology & oncology, 2015-09, Vol.4 (1), p.26-26, Article 26

2015

Volltextzugriff (PDF)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

Journal of clinical oncology, 2023-11, Vol.41 (32), p.4993-5004

2023

Volltextzugriff (PDF)

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

Journal of clinical oncology, 2018-12, Vol.36 (34), p.3361-3369

2018

Volltextzugriff (PDF)

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

PloS one, 2010-01, Vol.5 (1), p.e8893-e8893

2010

Volltextzugriff (PDF)

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

Value in health, 2024-05, Vol.27 (5), p.607-613

2024

Volltextzugriff (PDF)

Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis

Cells (Basel, Switzerland), 2022-01, Vol.11 (1), p.49

2022

Volltextzugriff (PDF)

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

Journal of clinical oncology, 2011-06, Vol.29 (18), p.e564-e565

2011

Volltextzugriff (PDF)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

Blood and lymphatic cancer, 2016-01, Vol.6 (Issue 1), p.7-19

2016

Volltextzugriff (PDF)

Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.6571-6571

2024

Volltextzugriff (PDF)

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Biology of blood and marrow transplantation, 2020-06, Vol.26 (6), p.1160-1170

2020

Volltextzugriff (PDF)

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

Leukemia research reports, 2013, Vol.2 (2), p.64-66

2013

Volltextzugriff (PDF)

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7018-7018

2023

Volltextzugriff (PDF)

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7017-7017

2023

Volltextzugriff (PDF)

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7057-TPS7057

2021

Volltextzugriff (PDF)

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7016-7016

2023

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(33)
Tagungsberichte
(1)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients

Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies

Altered Ca2+ Homeostasis in Red Blood Cells of Polycythemia Vera Patients Following Disturbed Organelle Sorting during Terminal Erythropoiesis

Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

Ruxolitinib: a targeted treatment option for patients with polycythemia vera

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years

Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial

Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?

Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study

Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis

Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF)

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study

Aktive Filter

Suchergebnisse filtern